BR112021017147A2 - Proteínas de domínio ccn recombinantes e proteínas de fusão - Google Patents
Proteínas de domínio ccn recombinantes e proteínas de fusãoInfo
- Publication number
- BR112021017147A2 BR112021017147A2 BR112021017147A BR112021017147A BR112021017147A2 BR 112021017147 A2 BR112021017147 A2 BR 112021017147A2 BR 112021017147 A BR112021017147 A BR 112021017147A BR 112021017147 A BR112021017147 A BR 112021017147A BR 112021017147 A2 BR112021017147 A2 BR 112021017147A2
- Authority
- BR
- Brazil
- Prior art keywords
- proteins
- recombinant
- ccn
- fusion
- fusion proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163970.7A EP3711772A1 (en) | 2019-03-20 | 2019-03-20 | Recombinant proteins and fusion proteins |
| PCT/EP2020/057773 WO2020188081A1 (en) | 2019-03-20 | 2020-03-20 | Recombinant ccn domain proteins and fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017147A2 true BR112021017147A2 (pt) | 2021-11-09 |
Family
ID=66102364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017147A BR112021017147A2 (pt) | 2019-03-20 | 2020-03-20 | Proteínas de domínio ccn recombinantes e proteínas de fusão |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606602B2 (https=) |
| EP (2) | EP3711772A1 (https=) |
| JP (1) | JP7600135B2 (https=) |
| KR (1) | KR20210142681A (https=) |
| CN (1) | CN113747912B (https=) |
| AU (1) | AU2020243073B2 (https=) |
| BR (1) | BR112021017147A2 (https=) |
| CA (1) | CA3133740A1 (https=) |
| IL (1) | IL285930B2 (https=) |
| MX (1) | MX2021011407A (https=) |
| SG (1) | SG11202109738QA (https=) |
| WO (1) | WO2020188081A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| GB202400055D0 (en) * | 2024-01-03 | 2024-02-14 | Tribune Therapeutics Ab | Use of ccn domain-containing proteins for the treatment of disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| GB8909916D0 (en) | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1999047556A2 (en) * | 1998-03-19 | 1999-09-23 | Trustees Of Tufts College | Novel heparin-induced ccn-like molecules and uses therefor |
| JP4202128B2 (ja) * | 2000-10-16 | 2008-12-24 | ジェネンテック・インコーポレーテッド | Ｗｉｓｐポリペプチドを用いる治療方法 |
| CN1835763B (zh) | 2003-06-20 | 2011-04-20 | 妙甯公司 | Ccn1组合物和方法 |
| FR2858234B1 (fr) * | 2003-08-01 | 2007-09-14 | Centre Nat Rech Scient | Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers |
| EP1771467A2 (en) | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| ES2395260T3 (es) * | 2005-01-10 | 2013-02-11 | Rosalind Franklin University Of Medicine And Science | Proteína CCN3 para su utilización en el tratamiento y el diagnóstico de enfermedades renales |
| DK1853631T3 (en) * | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| US20100144641A1 (en) | 2005-09-12 | 2010-06-10 | Popel Aleksander S | Compositions Having Antiangiogenic Activity and Uses Thereof |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US20080207489A1 (en) | 2007-02-21 | 2008-08-28 | John Castellot | Use of CCN5 for treatment of smooth muscle proliferation disorders |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| DK3061817T3 (en) * | 2009-04-30 | 2019-03-04 | Kao Corp | Alkaline protease variants |
| TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
| CA2773737C (en) | 2009-09-09 | 2021-11-16 | Pharmain Corporation | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same |
| ES2688978T3 (es) | 2009-11-23 | 2018-11-07 | Amgen Inc. | Anticuerpo monomérico Fc |
| KR101187814B1 (ko) | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
| EP2552462B1 (en) | 2010-04-02 | 2015-12-16 | Rosalind Franklin University of Medicine and Science | Ccn3 peptides and analogs thereof for therapeutic use |
| US9114112B2 (en) * | 2010-04-02 | 2015-08-25 | Rosalind Franklin University Of Medicine And Science | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses |
| ES2630031T3 (es) * | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| WO2014008582A1 (en) | 2012-07-11 | 2014-01-16 | The University Of Western Ontario | Method of treating wounds with penostin and/or ccn2 |
| US20140271641A1 (en) | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| EP3842451A1 (en) | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| WO2016197071A1 (en) | 2015-06-05 | 2016-12-08 | New York University | Compositions and methods for anti-staphylococcal biologic agents |
| GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| CN105396136B (zh) * | 2015-11-23 | 2018-10-30 | 上海交通大学医学院附属第九人民医院 | CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用 |
| EP3192806A1 (en) | 2016-01-13 | 2017-07-19 | Affiris AG | Alpha chain of the high-affinity ige receptor (fceria) |
| AU2017232546B2 (en) | 2016-03-14 | 2024-05-02 | Universitetet I Oslo | Engineered immunoglobulins with altered FCRN binding |
| US10028906B2 (en) | 2016-03-22 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Method and kit for treating a solid tumor and associated desmoplasia |
| EP3494128B1 (en) | 2016-08-04 | 2023-11-29 | Stichting VUmc | Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon |
| US20180127478A1 (en) | 2016-09-16 | 2018-05-10 | Wei-Chiang Shen | SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY |
| KR20180099537A (ko) * | 2017-02-28 | 2018-09-05 | 주식회사 파이안바이오테크놀로지 | 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제 |
| KR102008407B1 (ko) | 2017-09-05 | 2019-08-08 | 한국생명공학연구원 | 코돈 최적화된 il-21 및 이의 용도 |
| WO2019071007A1 (en) | 2017-10-05 | 2019-04-11 | New York Genome Center, Inc. | METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM |
-
2019
- 2019-03-20 EP EP19163970.7A patent/EP3711772A1/en not_active Withdrawn
-
2020
- 2020-03-20 US US17/440,576 patent/US12606602B2/en active Active
- 2020-03-20 CA CA3133740A patent/CA3133740A1/en active Pending
- 2020-03-20 EP EP20711209.5A patent/EP3941507A1/en active Pending
- 2020-03-20 SG SG11202109738Q patent/SG11202109738QA/en unknown
- 2020-03-20 MX MX2021011407A patent/MX2021011407A/es unknown
- 2020-03-20 KR KR1020217033515A patent/KR20210142681A/ko not_active Ceased
- 2020-03-20 CN CN202080023396.5A patent/CN113747912B/zh active Active
- 2020-03-20 IL IL285930A patent/IL285930B2/en unknown
- 2020-03-20 JP JP2021556442A patent/JP7600135B2/ja active Active
- 2020-03-20 AU AU2020243073A patent/AU2020243073B2/en active Active
- 2020-03-20 WO PCT/EP2020/057773 patent/WO2020188081A1/en not_active Ceased
- 2020-03-20 BR BR112021017147A patent/BR112021017147A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3711772A1 (en) | 2020-09-23 |
| MX2021011407A (es) | 2022-01-24 |
| CN113747912A (zh) | 2021-12-03 |
| US20220144903A1 (en) | 2022-05-12 |
| US12606602B2 (en) | 2026-04-21 |
| WO2020188081A1 (en) | 2020-09-24 |
| AU2020243073A1 (en) | 2021-11-11 |
| CN113747912B (zh) | 2025-04-04 |
| IL285930B2 (en) | 2025-01-01 |
| JP2022525661A (ja) | 2022-05-18 |
| SG11202109738QA (en) | 2021-10-28 |
| EP3941507A1 (en) | 2022-01-26 |
| IL285930A (en) | 2021-10-31 |
| CA3133740A1 (en) | 2020-09-24 |
| AU2020243073B2 (en) | 2025-06-05 |
| KR20210142681A (ko) | 2021-11-25 |
| JP7600135B2 (ja) | 2024-12-16 |
| IL285930B1 (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017147A2 (pt) | Proteínas de domínio ccn recombinantes e proteínas de fusão | |
| CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| UY40420A (es) | Formulación que comprende una superóxido dismutasa | |
| MX2022005252A (es) | Composiciones de escherichia coli y metodos de las mismas. | |
| ES2676499T3 (es) | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
| MX2019003298A (es) | Proteinas de union recombinantes y sus usos. | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
| BR112018075363A2 (pt) | neurotoxinas botulínicas manipuladas | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| CR20180509A (es) | Contorsbody - un ligante de diana monocatenario | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| BR122020006914B8 (pt) | Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| CO2023005372A2 (es) | Composiciones de escherichia coli y métodos de las mismas | |
| Fae et al. | PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular tissue, are the target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| BR112013013548B8 (pt) | Proteína de fusão anticancerígena | |
| MX2018013778A (es) | Mutante cd200 y sus usos. | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |